Yehuda Shoenfeld

Prof. Yehuda Shoenfeld

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2021 in Antibodies
Verified
Journal Article
Open access
PDF file
IPIrina Pashnina
Irina Pashnina
IKIrina Krivolapova
Irina Krivolapova
TFTamara Viktorovna Fedotkina
Tamara Viktorovna Fedotkina
YSYehuda Shoenfeld
Yehuda Shoenfeld
MCMargarita Chereshneva
Margarita Chereshneva
VCValeriy Chereshnev
Valeriy Chereshnev
The incidence of autoimmune diseases is increasing. Antinuclear antibody (ANA) testing is a critical tool for their diagnosis. However, ANA prevalence in healthy persons has increased over the last decades, especially among young people. ANA in health occurs in low concentrations, with a prevalence up to 50% in some populations, which demands a cutoff revision. This review deals with the origin and probable physiological or compensatory function of ANA in health, according to the concept of immunological clearance, theory of autoimmune regulation of cell functions, and the concept of functional autoantibodies. Considering ANA titers ≤1:320 as a serological marker of autoimmune diseases seems inappropriate. The role of anti-DFS70/LEDGFp75 autoantibodies is highlighted as a possible anti-risk biomarker for autoimmune rheumatic disorders. ANA prevalence in health is different in various regions due to several underlying causes discussed in the review, all influencing additive combinations according to the concept of the mosaic of autoimmunity. Not only are titers, but also HEp-2 IFA) staining patterns, such as AC-2, important. Accepting autoantibodies as a kind of bioregulator, not only the upper, but also the lower borders of their normal range should be determined; not only their excess, but also a lack of them or “autoimmunodeficiency” could be the reason for disorders.

Verified
Journal Article
Open access
PDF file
YSYehuda Shoenfeld
Yehuda Shoenfeld
Leonid ChurilovLeonid Churilov
Leonid Churilov
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
Fibromyalgia is a disorder characterized by chronic widespread pain and non-pain symptoms, such as fatigue, dysautonomia, and cognitive and sleep disturbances. Its pathogenesis and treatment continue to be the subject of debate. We highlight the role of three mechanisms—autoimmunity, neuroinflammation, and small fiber neuropathy—in the pathogenesis of the disease. These mechanisms are shown to be closely interlinked (also on a molecular level), and the review considers the implementation of this relationship in the search for therapeutic options. We also pay attention to chronic fatigue syndrome, which overlaps with fibromyalgia, and propose a concept of “autoimmune hypothalamopathy” for its pathogenesis. Finally, we analyze the molecular mechanisms underlying the neuroinflammatory background in the development of adverse events following HPV vaccination and suggesting neuroinflammation, which could exacerbate the development of symptoms following HPV vaccination (though this is hotly debated), as a model for fibromyalgia pathogenesis.

1 April 2019 in Autoimmunity Reviews
Verified
Journal Article
Closed access
YSYehuda Shoenfeld
Yehuda Shoenfeld
YSYuri V. Shubik
Yuri V. Shubik
MEMikhail V. Erman
Mikhail V. Erman
Leonid ChurilovLeonid Churilov
Leonid Churilov
DKDarja Kanduc
Darja Kanduc
YSYehuda Shoenfeld
Yehuda Shoenfeld

19 January 2022 in Pathophysiology
Verified
Journal Article
Open access
PDF file
NGNatali Gavrilova
Natali Gavrilova
LSLidiia Alexandrovna Soprun
Lidiia Alexandrovna Soprun
MLMaria Lukashenko
Maria Lukashenko
YSYehuda Shoenfeld
Yehuda Shoenfeld
TFTamara Viktorovna Fedotkina
Tamara Viktorovna Fedotkina
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
Fibromyalgia can be defined as a chronic pain condition, affecting the musculoskeletal system, etiology and pathophysiology of which is sufficiently understudied. Despite the fact that many authors consider this entity to be a manifestation of central sensitization, and not an autoimmune disease, the high prevalence of fibromyalgia in patients with post-COVID-19 conditions requires taking a fresh look at the causes of the disease development. During the patient examination, the authors identified a combination of symptoms that occurs so often, that they can be carefully described as a clinical pattern. These manifestations include young age, female gender, joint hypermobility, the onset of pain after COVID-19, physical traumatization of one particular tendon and the development of the fibromyalgia pain syndrome during the next several weeks. As well as an increase in the titer of antinuclear antibodies and some other systemic inflammation factors. It can be assumed with great caution that local damage to the connective tissue in patients with joint hypermobility, having COVID-19 as a trigger factor can lead to the development of fibromyalgia syndrome. This article presents three clinical cases that illustrated this hypothesis.

18 January 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
YSYehuda Shoenfeld
Yehuda Shoenfeld
NGNatali Gavrilova
Natali Gavrilova
APAlina A. Poletaeva
Alina A. Poletaeva
APAlexander I. Pukhalenko
Alexander I. Pukhalenko
IKIrina A. Koshkina
Irina A. Koshkina
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
Recent studies provide some evidence for the contribution of antibody-mediated autoimmune mechanisms to the nature of fibromyalgia (FM) and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Much attention was paid to the autoantibodies (AAb) targeting G protein-coupled receptors as natural components of the immune system. However, the natural AAb network is much more extensive, and has not been previously investigated in these disorders. The enzyme immunoassays ELI-Viscero-Test and ELI-Neuro-Test were used to determine changes in serum content of 33 natural AAb to neural, organ-specific and non-tissue-specific autoantigens (a) in 11 ME/CFS patients with comorbid FM; (b) in 11 ME/CFS patients without FM; (c) in 11 healthy controls. Individual AAb profiles and their correlation with some clinical symptoms were analyzed. Both patients with ME/CFS(−)FM and ME/CFS(+)FM were characterized by more frequent and pronounced deviations in the immunoreactivity to GABA-receptors than healthy controls. Although the level of other natural AAb did not differ between study groups, AAb correlation signatures were altered in patients compared to healthy controls. Both in patients and healthy controls the level of natural AAb to various neural and tissue-specific antigens correlated with the severity of fatigue, bodily pain, depression, anxiety, physical and mental health-related quality of life. Notably, widely different correlation patterns were observed between study groups. Findings from this pilot study provide some evidence that the homeostasis of autoimmune relationships, which are possibly a physiological part of our immune system, may be altered in FM and ME/CFS. The correlation of disease-induced perturbations in individual AAb profiles with some clinical symptoms may arise from the immune system’s ability to reflect qualitative and quantitative changes in antigenic composition of the body.

28 January 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
YMYulia Makarova
Yulia Makarova
YSYehuda Shoenfeld
Yehuda Shoenfeld
VSVladimir V. Salukhov
Vladimir V. Salukhov
BSBoris V. Sagun
Boris V. Sagun
AKAleksandr Korovin
Aleksandr Korovin
Leonid ChurilovLeonid Churilov
Leonid Churilov
The article describes how atherosclerosis and coronavirus disease 19 (COVID-19) may affect each other. The features of this comorbid pathogenesis at various levels (vascular, cellular and molecular) are considered. A bidirectional influence of these conditions is described: the presence of cardiovascular diseases affects different individuals’ susceptibility to viral infection. In turn, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can have a negative effect on the endothelium and cardiomyocytes, causing blood clotting, secretion of pro-inflammatory cytokines, and thus exacerbating the development of atherosclerosis. In addition to the established entry into cells via angiotensin-converting enzyme 2 (ACE2), other mechanisms of SARS-CoV-2 entry are currently under investigation, for example, through CD147. Pathogenesis of comorbidity can be determined by the influence of the virus on various links which are meaningful for atherogenesis: generation of oxidized forms of low-density lipoproteins (LDL), launch of a cytokine storm, damage to the endothelial glycocalyx, and mitochondrial injury. The transformation of a stable plaque into an unstable one plays an important role in the pathogenesis of atherosclerosis complications and can be triggered by COVID-19. The impact of SARS-CoV-2 on large vessels such as the aorta is more complex than previously thought considering its impact on vasa vasorum. Current information on the mutual influence of the medicines used in the treatment of atherosclerosis and acute COVID-19 is briefly summarized.